Article Text

Download PDFPDF

921 ADGRG1 cell surface expression enriches for neoantigen-reactive CD4 lymphocytes from human tumors
  1. Kyle J Hitscherich1,
  2. Sri Krishna2,
  3. Steven A Rosenberg2 and
  4. Frank Lowery1,2
  1. 1National Institute of Health, Gaithersburg, MD, USA
  2. 2National Cancer Institute, Bethesda, MD, USA

Abstract

Background Treatment with naturally occurring antitumor T cells, or cells genetically modified to express their receptors (TCRs), has shown efficacy in patients with advanced malignancies.1–3 Previous studies have demonstrated success in defining the unique transcriptomic states of antitumor CD8+ and CD4+ tumor infiltrating lymphocytes (TIL) in human cancer.4–6 We recently described a CD4+ TIL transcriptomic signature (CD4+ NeoTCR) for predicting neoantigen-reactive CD4+ TCRs from metastatic tumors.7

As opposed to transcriptomic analysis, cell surface marker-based isolation of antitumor TIL would allow growth and expansion of cells for downstream applications. Previous work demonstrated that reactivity to tumor cell lines, oncoviral proteins, and patient-specific neoantigens are reliably enriched when selecting for CD8+ lymphocytes expressing specific surface markers.8–11 Although enrichment for neoantigen reactivity amongst CD4+ TIL has been demonstrated with such markers as PD-1hiCD39+ (4.5% median reactive cells within population) and PD-1/ICOS co-expression (10%), an optimal signature for CD4+ TIL has yet to be defined.12 13 Thus, additional markers warrant investigation.

Methods Tumor digest of metastatic lesions from three patients with stage IV colon adenocarcinoma underwent single cell transcriptomic and CITE (cellular indexing of transcripts and epitopes)-seq. The CD4+ NeoTCR transcriptomic signature was used to identify likely neoantigen-reactive CD4+ clusters within samples.7 CITE-seq was used to examine the expression of 130 cell surface proteins to determine differentially expressed proteins that correspond to the CD4+ NeoTCR transcriptomic state. Several surface proteins expressed across CD4+ NeoTCR clusters of interest were selected as candidates and their performance isolating neoantigen-reactive CD4+ TCRs was validated using FACS followed by scTCR-seq.

Results CITE-seq analysis showed several candidate cell surface protein markers that were found across CD4+ NeoTCR clusters including PD-1, ADGRG1, CD86, and CD57. FACS-sorting CD4+ cells expressing candidate markers, followed by scTCR-seq, showed ADGRG1 was the most successful single marker in isolating cells found in the CD4+ NeoTCR transcriptomic states within two patients (34.21–68.57%). From our library of 34 experimentally defined neoantigen-reactive CD4+ TCRs, ADGRG1 enrichment of neoantigen-reactive CD4+ TIL was 2.9-fold greater compared to bulk CD4+ cells (21.21% reactivity vs. 7.22%). The next best markers were CD86 with a 2.0-fold (14.71%), and PD-1 with a 1.73-fold (12.5%) improved capture of neoantigen-reactive CD4+ TIL.

Conclusions ADGRG1, as a single cell surface marker, showed the highest efficiency in isolating neoantigen-reactive CD4+ TCRs from metastatic solid tumors and could be an important marker in enriching for neoantigen-reactive CD4+ TIL. Future experiments will further evaluate these markers of interest in prospective patient samples.

References

  1. Robbins PF, Morgan RA, Feldman SA. Tumor Regression in Patients with Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. J Clin Oncol. 2011;29(7):917–924.

  2. Leidner R, Silva NS, Huan H. Neoantigen T-cell Receptor Gene Therapy in Pancreatic Cancer. N Engl J Med. 2022;386(22):2112–2119.

  3. Kim SP, Vale NR, Zacharakis N. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors. Cancer Immunol Res. 2022;10(8):932–946.

  4. Oliveira G, Stromhaug K, Klaeger S. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature. 2021;596(7870):119–125.

  5. Oliveira G, Stromhaug K, Cieri N. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature 2022;605(7910):532–538.

  6. Krishna S, Lowery FJ, Copeland AR. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 2020;370(6522):1328–1334.

  7. Lowery FJ, Krishna S, Yossef R. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 2022;375:877–884.

  8. Duhen T, Duhen R, Montler R. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nature Communications 2018;9:2724

  9. Gros A, Robbins PF, Yao X. PD-1 identifies the patient-specific CD8 tumor-reactive repertoire infiltrating human tumors. JCI. 2014;124(5):2246–2259.

  10. Gros A, Tran E, Parkhurst MR. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1 lymphocytes. JCI. 2019;129(11):4992–5004.

  11. Chatani PD, Lowery FJ, Parikh NB. Cell Surface Marker-Based Capture of Neoantigen-Reactive CD8 T-cell Receptors From Metastatic Tumor Digests. J Immunother Cancer. 2023;11(5):e006264.

  12. Duhen R, Fesneau O, Samson KA. PD-1 and ICOS Coexpression Identifies Tumor-Reactive CD4 T Cells in Human Solid Tumors. J Clin Invest. 2022;132(12):e156821.

  13. Palomeroo J, Pansiello C, Lozano-Rabella M. Biomarkers of tumor-reactive CD4 and CD8 TILs associate with improved prognosis in endometrial cancer. J Immunother Cancer. 2022;10(12):e005443.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.